Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

Summary

The trial consists of a dose escalation, to establish the safety of ofatumumab in RRMS patients. A 48-week treatment period followed by an individualized follow-up period until normalization of peripheral B-cell counts or Immunoglobulin G (IgG) levels.

Timeline

Start

2008-05

Primary completion

2010-05

Completion

2011-10

Drugs

Indications